Stanley N. Lapidus

AIMBE College of Fellows Class of 2014
For outstanding contributions to diagnostic medicine used to make treatment decisions in tens of millions of patients throughout the world.

SynapDx Corporation CEO Stan Lapidus Named to AIMBE’s College of Fellows

Via Business Wire | March 25, 2014

LEXINGTON, Mass.–(BUSINESS WIRE)–SynapDx Corporation today announced that founder and CEO Stanley Lapidus was inducted to the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. This honor recognizes Lapidus’ pioneering contributions to the field of biomedical engineering.

In 2010, Lapidus founded SynapDx to develop a novel blood test to enable the earlier detection of autism. In the U.S., the average age of diagnosis for autism spectrum disorders (ASD) is 4.5 years. However, beneficial therapies and interventions can begin at much younger ages. The SynapDx test is designed to detect patterns of gene expression to help pediatricians identify children at risk of ASD earlier than they do today.